Antibody-Drug Conjugate (ADC) Characterization
Antibody-drug conjugate (ADC) characterization is an analytical technique used to evaluate the structure, stability, purity, and functionality of ADCs. ADCs are a class of targeted therapeutic drugs composed of monoclonal antibodies, linkers, and small molecule cytotoxic drugs. They achieve high efficacy in cancer treatment by precisely delivering cytotoxic drugs to cancer cells through the high specificity binding ability of antibodies, while reducing the side effects on non-target cells. Due to the complex structure and diverse components of ADCs, precise characterization analysis is required during their development and production to ensure quality, stability, and therapeutic efficacy. The core elements of ADC characterization include drug-to-antibody ratio (DAR), linkage site analysis, structural integrity, purity analysis, and biological activity assessment. The DAR is a key parameter that measures the average number of drug molecules attached to each antibody molecule in ADCs. It is typically determined using methods such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), or capillary electrophoresis (CE). The size of the DAR directly affects the efficacy and safety of ADCs. If the DAR is too low, drug loading is insufficient, affecting anti-cancer efficacy; if the DAR is too high, it may affect antibody stability and drug distribution in vivo, leading to increased side effects. Therefore, accurate determination of the DAR is one of the core aspects of quality control for ADCs. Linkage site analysis is another aspect of ADC characterization. Drug molecules in ADCs are usually covalently linked to lysine (Lys) or cysteine (Cys) residues of the antibody through chemical linkers. Different linkage sites may affect the stability, uniformity, and biological activity of ADCs. Liquid chromatography-mass spectrometry (LC-MS) can be used to analyze the distribution of linkage sites in ADCs, thereby optimizing the conjugation strategy and ensuring good stability and targeting properties in vivo.
Structural integrity analysis is crucial for ensuring the quality of ADCs. Changes in the antibody structure, such as aggregate formation, degradation, or partial reduction, may affect the stability and functionality of ADCs. Therefore, various biophysical and biochemical methods are employed for structural characterization, including circular dichroism (CD) to measure the secondary structure of antibodies, differential scanning calorimetry (DSC) to detect antibody thermal stability, and dynamic light scattering (DLS) to assess the aggregation state of ADCs. Additionally, complete ADC molecules need to be evaluated for glycosylation modifications, as glycosylation affects ADCs' in vivo half-life and may influence their immunogenicity. Therefore, glycosylation analysis using liquid chromatography-mass spectrometry (LC-MS) or capillary electrophoresis (CE) is an essential step in the ADC characterization process.
Purity analysis is an indispensable part of antibody-drug conjugate (ADC) characterization. As ADCs are complex biological formulations formed through chemical modifications, various impurities such as unconjugated antibodies, free drugs, aggregates, and fragmented products may form during production. These impurities can affect the biological activity of ADCs and even lead to adverse reactions. To assess the purity of ADCs, methods such as high-performance liquid chromatography (HPLC), size exclusion chromatography (SEC), and capillary electrophoresis (CE) are commonly used. Specifically, SEC-HPLC can effectively distinguish ADC monomers, aggregates, and degradation products, providing data for quality control.
In addition to physicochemical analysis, assessing the biological activity of ADCs is equally important. The antibody part of ADCs needs to maintain high affinity for target cell antigens, while the drug part needs to be effectively released within cells to kill cancer cells. Therefore, in vitro activity assessments of ADCs typically include antigen binding experiments (such as ELISA, surface plasmon resonance SPR), cytotoxicity assays (MTT, CCK-8), intracellular drug release experiments (fluorescence detection, flow cytometry), etc. Additionally, in vivo pharmacokinetics (PK) and biodistribution experiments help study the metabolic pathways and targeted distribution of ADCs in animal bodies, providing key reference data for clinical application.
Another aspect of antibody-drug conjugate (ADC) characterization is stability analysis. Due to the complex structure of ADCs, degradation, detachment, or aggregation may occur during storage and circulation in vivo, affecting their efficacy and safety. Therefore, long-term and accelerated stability studies are needed to evaluate the stability of ADCs under different temperatures, pH values, light exposure, and storage conditions. These studies typically use SEC-HPLC, LC-MS, and DLS methods to monitor ADC degradation, and combine biological activity experiments to verify functional changes.
Biocytogen Pharmaceuticals is committed to providing high-quality analysis services for antibody-drug conjugates (ADCs). We have advanced analytical platforms and professional technical teams to offer comprehensive ADC analysis to clients, including DAR determination, linkage site analysis, structural integrity assessment, purity testing, and biological activity evaluation.
Biocytogen Pharmaceuticals - Characterization of biological products, a high-quality service provider for multi-group biological mass spectrometry testing.
Related services:
How to order?
